Psychotic symptoms are common in Alzheimer’s disease (AD) and are associated with adverse outcomes for both patients and caregivers. Management of these symptoms is difficult for various reasons. In this article, we review the management of psychosis in AD, including a discussion of novel therapeutics currently under development.
Analysis of new data presented at the European Academy of Neurology (EAN) congress 2024, delivered by an expert faculty in the field of Neurology.
Diabetic striatopathy (DS) refers to an uncommon hyperglycaemic condition usually associated with chorea or ballism and a unique, reversible abnormality of the basal ganglia on the computed tomography (CT) scan and/or magnetic resonance imaging (MRI). This paper presents two cases of DS, both with drowsiness and cognitive dysfunction, but without hyperkinetic movement disorders; these cases present specific neuroimaging features and high blood glucose levels that led to the diagnosis. Both patients showed clinical improvement after initiating treatment for hyperglycaemia.
Prof. Leontino Battistin shares his thoughts on the potential impact on the field of Neurology.
Education, Conference Coverage and Articles
Cognitive impairment is the hallmark symptom of Alzheimer’s disease (AD); however, neuropsychiatric symptoms (NPS), including psychosis, agitation and mood disturbances, are common not only in AD but also in Parkinson’s disease, dementia with Lewy bodies, frontotemporal dementia and ...
Diabetic striatopathy (DS) is a rare hyperglycaemic condition associated with one or both of the following criteria: (1) acute-onset chorea–ballism (random, flowing and nonsuppressible involuntary movements) and (2) striatal hyperdensity on computed tomography (CT) scan or T1-weighted magnetic resonance imaging (...
Article highlights Multiple screening tests are available to screen patients for cognitive impairment, and the Confusion Assessment Method is a helpful test to screen for delirium in the immediate postoperative period. Medicine reconciliation and identification and removal of potentially inappropriate ...
Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages ...
Watch leading experts explain the shifting diagnostic paradigm in Alzheimer’s disease using case studies demonstrating the utility of biomarkers
Watch leading experts discuss recent developments in Alzheimer’s disease, including the use of biomarkers.
Watch leading spinal muscular atrophy (SMA) experts discuss current trends in pharmacologic and non-pharmacologic therapy use, barriers to use of these standards of care, and potential solutions to improve access as patients age.
Share your knowledge, influence clinical practices and enhance patient care in Neurology today!
What is the Stroke Action Plan for Europe? Stroke is one of the most enormous burdens to healthcare services.1 Despite our combined efforts, it affects more than one million people annually in Europe. Although we have abundant knowledge regarding stroke ...
Welcome to the latest edition of touchREVIEWS in Neurology. We are excited to present a collection of articles that showcase the latest advancements and diverse perspectives in neurological research and treatment. This issue features insightful reviews and editorials from esteemed ...
Neuromyelitis optica spectrum disorders (NMOSD) are a group of relapsing autoimmune diseases of the central nervous system. The clinical hallmarks of NMOSD are myelitis and optic neuritis; however, a wider clinical spectrum has been recognized.1 The majority of patients with ...
Affecting over 70 million patients worldwide, epilepsy is a chronic neurological disorder characterized by intermittent bursts of hyper-synchronous neuronal discharges.1 The manifestations are variable but reflective of the unique milieu and biology of epileptogenic foci.2 Pharmacological treatment with antiepileptic drugs (AEDs) ...
Rescue medications are an important part of the treatment regimen for patients with intractable epilepsy, specifically those who experience seizure clusters or prolonged seizure episodes. Rescue medications are prescribed to end seizure activity quickly and effectively in order to prevent ...
Parkinson’s disease (PD) is characterized by prodromal and clinical stages; the clinical phase is characterized by a constellation of motor and non-motor symptoms (NMS).1 Despite the extensive discussions and publications of the clinical heterogeneity of PD,2 the precise heterogeneous ...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory autoimmune disease of the central nervous system (CNS) with a worldwide distribution.1 The first clinical description of NMOSD was made a century ago by Devic and Gault, who documented patients with ...
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by the degeneration of nigrostriatal dopaminergic neurons, with its incidence increasing globally.1 With disease progression, the benefit from medications shortens, and symptom control becomes strictly dependent on peripheral levodopa (...
Introduction The term 'stroke' is used to describe an adverse clinical state involving interference of blood circulation to the brain due to obstruction or rupture of blood vessels.1 Stroke was previously categorized into a cardiovascular disorder until the release of ...
Multiple sclerosis (MS) is a complex disease that can pose significant challenges in diagnosis, monitoring and treatment. Over the years, the quest for more precise and accessible diagnostic tools has led to the exploration of different fluid biomarkers in cerebrospinal ...
In the latest edition of touchREVIEWS in Neurology, we are pleased to present a collection of insightful articles that highlight the current landscape and future directions in neurological research and treatment. Firstly, Rajvinder Karda opens this issue with a compelling ...
Duchenne muscular dystrophy (DMD) is an X-linked recessive, progressive and universally fatal disease in the spectrum of dystrophinopathies,1 with an incidence of 21.4 patients in 100,000 live male births worldwide.2,3 Historically, patients with DMD would lose ambulation by the age of 10 due ...
Learn about the latest advancements and current barriers in genetic counseling and testing from expert speaker, Jennifer Roggenbuck.
Watch leading experts discuss advances in the early diagnosis and treatment of Alzheimer's disease in this engaging symposium, originally presented at the Spanish Neurological Society.
Introducing the Editorial Board of touchREVIEWS in Neurology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
Multiple sclerosis
Attending Neurologist at Cooper University Hospital, Cooper Neurological Institute, Cherry Hill, NJ, USA, Professor of Neurology at Cooper Medical School of Rowan University, Camden, NJ, USA, and Emeritus Professor of Neurology in the Academic Unit of Mental Health and Clinical Neurosciences at the University of Nottingham, Nottingham, UK
Prof. Cris S Constantinescu is the co-Editor-in-Chief of touchREVIEWS in Neurology. Cris Constantinescu is Attending Neurologist at Cooper University Hospital, Cooper Neurological Institute, Cherry Hill, NJ, USA, Professor of Neurology at Cooper Medical School of Rowan University, Camden, NJ, USA, and Emeritus Professor of Neurology in the Academic Unit of Mental Health and Clinical Neurosciences at the University of Nottingham, Nottingham, UK. He graduated with an MD from Boston University School of Medicine, USA, in 1988. As a recipient of the physician-scientist award from the National Institutes of Health, USA, he completed a PhD in immunology at the University of Pennsylvania in 1998. He has completed an internship and a residency in neurology and fellowships in neuroimmunology and neurorehabilitation. He was appointed honorary consultant neurologist and senior lecturer in neurology at the University of Nottingham 2000–2001. In 2004, he was appointed Professor of Neurology and Chair in Neurology at the University of Nottingham, a post he held until 2021. He has authored or co-authored over 200 articles in international journals. His research interests are immune regulation in inflammatory diseases of the nervous system, in particular multiple sclerosis, neuroimaging, clinical trials and cognitive neurology. He is currently involved in the care of numerous patients with neuroimmunological and neurodegenerative diseases.
Neuromuscular diseases
Professor and Division Chief for Neuromuscular Medicine at the Department of Neurology at Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA
Said R Beydoun, MD, FAAN, is Professor and Division Chief for Neuromuscular Medicine at the Department of Neurology at Keck School of Medicine, University of Southern California (USC). He is Program Director of the Clinical Neurophysiology Fellowship. As a principal investigator, Dr Beydoun has participated in multiple research clinical trials. His clinical and research areas of expertise in the field of neuromuscular medicine include amyotrophic lateral sclerosis (ALS), myasthenia gravis, peripheral neuropathy (including chronic inflammatory demyelinating polyneuropathy), multifocal motor neuropathy and transthyretin-related amyloid neuropathy. He has published in several scientific journals on topics related to neuromuscular diseases and is co-Editor-in-Chief of touchREVIEWS in Neurology. He is an elected fellow of the American Academy of Neurology and a fellow of the American Association of Neuromuscular and Electrodiagnostic Medicine; a member of the medical/scientific advisory board of the Myasthenia Gravis Foundation of America; Medical Director of the Certified ALS Treatment Center of Excellence at Keck USC; and holds board certification by the American Board of Psychiatry and Neurology in neurology, clinical neurophysiology, neuromuscular medicine and pain medicine.
Movement disorders
Professor of Neurology/Movement Disorders at King’s College Hospital and King’s College London and Director of the Parkinson Foundation International Centre of Excellence at King’s College London, UK
Prof. K. Ray Chaudhuri is Professor of Neurology/Movement Disorders at King’s College Hospital and King’s College London and Director of the Parkinson Foundation International Centre of Excellence at King’s College. He is Chairman of the Industry Engagement Committee, and Co Chair Task force of the Parkinson Wellness committee of the Movement Disorders Society (MDS and Ex Chair Membership and Public Relations Committee of the Movement Disorders Society (MDS), was a member of the MDS Congress Scientific Programme Committee (2013-2017) and is Founder and Ex Chairman and current steering group member of the MDS Non-Motor Parkinson’s Disease Study Group and a member of the MDS-ES Education committee and Evidence Based Medicine committee (Nonmotor symptoms). He was the founder -Editor-in-Chief of the njp Parkinson’s Disease (2020 impact factor >8), Guest Editor for special editions of Frontiers in Neurology and Journal of Parkinson’s Disease, reviewer for all mainstream movement disorders journals as well as JAMA, Neurology, Annals of Neurology, BMJ, Brain, Lancet, and Journal of Neurology, Neurosurgery, and Psychiatry. He serves as an advisor (MHRA health technology and scientific advisor) to the UK National Institute for Health and Care Excellence, NHS England, General Medical Council as well as Parkinson’s UK and Parkinson’s Europe.
Prof. Chaudhuri is the author of over 500 articles, co-editor of 5 books on Parkinson’s disease and restless legs syndrome, and winner of the British Medical Association Book Awards commendation in 2015 and 2017. He is also the recipient of 2018 Jay Van Andel Award Outstanding Achievement in Parkinson’s Disease Research (pioneering holistic assessments and non-motor subtypes), as well as National Institute for Health Research/Royal College of Physicians award for outstanding research leadership in 2017. He was elected honorary member of the Movement Disorders Society in 2021, Honorary Professor Brasov University, Honorary Professor SRM University, India and received the UK NHS Gold merit award in 2021 for excellence in research and clinical service. In 2023 he was featured as “role model” in British Medical Journal. He has been a guest lecturer worldwide, including in Japan, China, Taiwan, Vietnam, Thailand, Singapore, Australia, India, Africa, the US, Russia, and Europe. In 2022/2023 he is ranked fourth in the world for Parkinson’s publications/expertise and expertise since 2014 and no 1 in the UK (expertscape: Parkinson’s disease). In 2024, an independent review in Frontiers journal by LI et al rated KRC as the one with most publications globally in nonmotor Parkinson’s since 2013 (Li et al , DOI 10.3389/fnagi.2024.1335550). In 2024 Prof. Chaudhuri will inaugurate the Kings Parkinson Charity dedicated to research to promote day to day care for People with Parkinson and their carers in conjunction with Sir Nicholas Mostyn, founder of the BBC endorsed Movers and Shakers expert patients group.
Neurodegenerative Diseases
Professor of Neurology, University of Padova, Italy
Born in Fiume (actually Rijeka, Croatia) in 1939, graduated in Medicine at the University of Padova Medical School in 1963; Specialist in Neurology in 1967. During the years 1967-1970 he was Research Fellow at the Institute for Neurochemistry, Columbia University, New York, USA.
Full Professor of Neurology from 1980 and then Director of the Department of Neurosciences of the Medical School of the University of Padova till 2009. He was the Founder and Scientific Director of the Research Hospital for Neurorehabilitation, IRCCS San Camillo, Venice, from 2005 to 2014.
He has been member of the Executive Council of the Italian Society of Neurology and the President of the Italian Society for Parkinson’s Disease; he was a member of the Executive Committee on Extrapyramidal Disorders, chaired by Melvin Yahr, and after by Donald Calne, and of the one on Dementia of the World Federation of Neurology and, in 2009, Chairman of the Research Group for Organization and Delivery of Neurological Services; he has been elected at the WCN in London Vice-President for Europe of the World Federation of Neurology for the years 2001-2005; also, he has been the President of the European Society for Clinical Neuropharmacology during the years 2000-2008; he is a member of numerous International Scientific Societies, and Fellow of the American Academy of Neurology. He has been also a member of the Editorial Board of international journals of neuroscience and clinical neurology.
He has organized various International Congresses and Symposia on specific themes of neuroscience; he was the President of the 11th World Congress on Parkinson’s Disease that was held for the first time in Italy, Rome, in 1994, and President of the 2nd World Congress on Neurorehabilitation held in Venice, in 2002, when the World Federation on Neurorehabilitation was founded; also, he has been the Honorary President of the XXV World Congress of Neurology held in Rome, Italy, in October 2021.
He has published more than 300 papers in various international and national journals and edited ten volumes on specific arguments of neurology; his main scientific interests have always been cerebral metabolism and function especially in degenerative diseases of the nervous system, like Parkinson’s and Alzheimer’s disease, as well as in cerebrovascular diseases and in neurorehabilitation.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.